New ZealandNew Zealand offers life-sciences companies a transparent, English-language regulatory environment anchored by Medsafe and a highly educated consumer base. Taevas delivers end-to-end market entry support so your brand moves from registration to revenue wit
Select an industry to see regulatory pathways, services, and how Taevas supports your New Zealand market entry.
Medsafe, New Zealand Medicines and Medical Devices Safety Authority
New Zealand's medical device market is valued at over NZD 1.5 billion and is regulated by Medsafe under the Medicines Act 1981 and the Medical Devices (Conformity Assessment) Regulations 2016. Devices are classified from Class I to Class IV based on risk, with higher-risk products requiring conformity assessment and WAND database registration. Taevas guides international manufacturers through every step, from classification and technical documentation to post-market surveillance obligations.
All medical devices sold in New Zealand must be entered on the Medsafe WAND database. Taevas prepares and submits all required product and manufacturer details to meet Medsafe listing requirements.
Class III and Class IV devices require a conformity assessment certificate from a recognised body before registration. Taevas coordinates with accredited conformity assessment bodies and prepares the technical file.
Importing medical devices into New Zealand requires compliance with Medsafe import requirements and MPI biosecurity checks. Taevas manages documentation, tariff classification, and border clearance logistics.
Medsafe requires ongoing adverse event reporting and periodic safety reviews for registered devices. Taevas establishes local surveillance systems and manages mandatory incident reporting on your behalf.
Taevas combines deep Medsafe and FSANZ regulatory expertise with on-the-ground commercial networks to give international life-sciences companies a fast, compliant, and commercially successful path into New Zealand.
Our team includes specialists with direct experience navigating Medsafe medicine consent applications, WAND device registration, and FSANZ novel food approvals, reducing submission errors and accelerating approval timelines for your New Zealand entry.
New Zealand's regulatory frameworks are closely aligned with Australia's TGA and FSANZ systems, and Taevas leverages this relationship to help clients pursue parallel market entry strategies across both markets efficiently.
Taevas pre-screens all regulatory dossiers against Medsafe and FSANZ requirements before submission, minimising requests for additional information and compressing typical approval timelines by weeks.
We maintain active relationships with medical device distributors, pharmaceutical wholesalers, pharmacy chains, and health food retailers across New Zealand, enabling rapid commercial activation post-registration.
Taevas has mapped New Zealand's key opinion leader landscape across medicine, pharmacy, and allied health, enabling targeted engagement strategies that build clinical credibility and accelerate product adoption.
Taevas has supported multiple international life-sciences brands through successful New Zealand market entry, delivering compliant registrations, commercial partnerships, and sustained revenue growth in this market.
Connect with our New Zealand market entry specialists today for a no-obligation assessment of your regulatory pathway, commercial opportunity, and the fastest route to revenue in this market.